Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Clopidogrel may stop 'Silent' strokes that lead to dementia

NCT ID NCT04698031

Prevention Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study looks at whether clopidogrel, a blood thinner, can prevent new silent brain infarctions (small, unnoticed strokes) in people who recently had a stroke or mini-stroke. Researchers will track 134 participants over 24 months using MRI scans and cognitive tests. The goal is to find a way to reduce the risk of future strokes and memory decline.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

134 people

The number who actually took part.

Started

Mar 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosis of ischemic stroke/TIA * \<90 days from onset of symptoms * initial MRI available * not receiving antiplatelet therapy at the time of admission * medical decision by the treating physician that antiplatelet therapy is indicated for secondary prevention (decision independent of the study and based on individual clinical decision for each patient). * baseline coated-platelet levels at 40% * willingness to participate in the study for 24 months Exclusion Criteria: * dementia (based on chart review or self/proxy report) * \> 90 days from onset of symptoms * initiation of anticoagulation or thrombolytics prior to phlebotomy * intracranial hemorrhage or bleeding diatheses * end-stage renal disease (ESRD) * inability to tolerate consenting or phlebotomy * prior adverse/allergic reactions to clopidogrel * treating physician deemed a different antiplatelet dose or dual antiplatelet therapy as the only treatment choice

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain infarction ischemic stroke transient ischemic attack MRI defined brain infarct prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Silent brain infarction

Contacts and locations

Locations

  • Oklahoma City VA Medical Center, Oklahoma City, OK

    Oklahoma City, Oklahoma, 73104-5007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.